DK1331938T3 - Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom - Google Patents

Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom

Info

Publication number
DK1331938T3
DK1331938T3 DK01983031T DK01983031T DK1331938T3 DK 1331938 T3 DK1331938 T3 DK 1331938T3 DK 01983031 T DK01983031 T DK 01983031T DK 01983031 T DK01983031 T DK 01983031T DK 1331938 T3 DK1331938 T3 DK 1331938T3
Authority
DK
Denmark
Prior art keywords
lactobacillus
strain
metabolic syndrome
risk factors
factors associated
Prior art date
Application number
DK01983031T
Other languages
English (en)
Inventor
Marie-Louise Johansson
Marek Naruszewicz
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Application granted granted Critical
Publication of DK1331938T3 publication Critical patent/DK1331938T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
DK01983031T 2000-11-10 2001-11-12 Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom DK1331938T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0004124A SE0004124D0 (sv) 2000-11-10 2000-11-10 New use
PCT/SE2001/002500 WO2002038165A1 (en) 2000-11-10 2001-11-12 Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome

Publications (1)

Publication Number Publication Date
DK1331938T3 true DK1331938T3 (da) 2007-02-12

Family

ID=20281779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01983031T DK1331938T3 (da) 2000-11-10 2001-11-12 Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom

Country Status (16)

Country Link
US (1) US20040048356A1 (da)
EP (1) EP1331938B1 (da)
JP (1) JP4200518B2 (da)
KR (2) KR20080047628A (da)
CN (1) CN1226039C (da)
AT (1) ATE343392T1 (da)
AU (2) AU2002214486B2 (da)
CA (1) CA2434035C (da)
DE (1) DE60124131T2 (da)
DK (1) DK1331938T3 (da)
ES (1) ES2269480T3 (da)
NO (1) NO330992B1 (da)
NZ (1) NZ525657A (da)
PL (1) PL203824B1 (da)
SE (1) SE0004124D0 (da)
WO (1) WO2002038165A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830750B1 (en) * 1998-10-01 2004-12-14 Probi Ab Reduction of oxidative stress factors with Lactobacillus plantarum
CN1293186C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1293187C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1237168C (zh) * 2002-10-30 2006-01-18 食品工业发展研究所 具有降低与同化胆固醇能力的耐酸与耐胆盐乳杆菌分离株
CN1293185C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
EP1931363B1 (en) * 2005-09-28 2015-11-18 Nordisk Rebalance A/S Treatment of ibd using both probiotic bacteria and fermented cereal as treatment effectors
PL1981516T3 (pl) * 2006-01-27 2019-03-29 Dupont Nutrition Biosciences Aps Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom
JP5229977B2 (ja) * 2006-09-08 2013-07-03 雪印メグミルク株式会社 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
JP5201832B2 (ja) * 2006-12-25 2013-06-05 花王株式会社 脂肪分解促進用皮膚外用剤
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
SE532899C2 (sv) 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
KR101010914B1 (ko) * 2008-04-28 2011-01-26 주식회사 엔유씨전자 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄
PL2411027T3 (pl) 2009-03-25 2015-04-30 Chr Hansen As Zastosowanie probiotyku do regulowania masy ciała
CN104784220A (zh) 2009-06-19 2015-07-22 杜邦营养生物科学有限公司 治疗糖尿病及相关病症的双歧杆菌
AU2010334993B2 (en) 2009-12-22 2015-07-09 Probi Ab Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
KR101426276B1 (ko) * 2012-08-16 2014-08-05 주식회사한국야쿠르트 심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변 형성을 억제하는 활성을 가지는 락토바실러스 플란타룸 ｈｙ７７１２를 유효성분으로 함유하는 제품
KR101470995B1 (ko) * 2013-08-30 2014-12-09 주식회사 바이오리쏘스 프로피온산 생산능을 갖는 미생물 및 그를 포함하는 조사료 조성물
KR101500974B1 (ko) * 2014-08-22 2015-03-13 (주) 에이투젠 항염증 및 대사성질환 개선 효능을 가지는 락토바실러스 플란타룸 hac01 균주 및 이의 용도
CN105105145B (zh) * 2015-09-14 2022-04-22 吉林省命之元生物科技有限公司 一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用
GB201519327D0 (en) 2015-11-02 2015-12-16 Optibiotix Health Ltd Composition
CN105567601A (zh) * 2016-01-29 2016-05-11 江苏绿科生物技术有限公司 一种植物乳杆菌及其应用
MY197201A (en) 2017-02-10 2023-05-31 Perfect China Co Ltd Novel probiotics bifidobacteria strains
JP7568202B2 (ja) * 2017-05-26 2024-10-16 ハウスウェルネスフーズ株式会社 メタボリックシンドロームの予防、改善又は治療用組成物
KR102063772B1 (ko) * 2019-07-23 2020-01-08 주식회사 메디오젠 혈당 강하 효과 및 항산화 효과를 갖는 유산균
CA3184700A1 (en) * 2020-07-01 2022-01-06 Guy Chamberland Cannabis plant residue and use thereof
CN112126604B (zh) * 2020-09-30 2022-05-17 江南大学 一株可降低高血压发生风险因子的植物乳杆菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501056D0 (sv) * 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
SE510753C2 (sv) * 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient

Also Published As

Publication number Publication date
NO330992B1 (no) 2011-09-05
US20040048356A1 (en) 2004-03-11
NO20032056L (no) 2003-05-08
EP1331938B1 (en) 2006-10-25
AU1448602A (en) 2002-05-21
JP4200518B2 (ja) 2008-12-24
CA2434035A1 (en) 2002-05-16
CA2434035C (en) 2011-06-07
PL362221A1 (en) 2004-10-18
CN1486189A (zh) 2004-03-31
DE60124131D1 (de) 2006-12-07
AU2002214486B2 (en) 2007-04-26
CN1226039C (zh) 2005-11-09
WO2002038165A1 (en) 2002-05-16
PL203824B1 (pl) 2009-11-30
NZ525657A (en) 2005-05-27
KR20040018304A (ko) 2004-03-03
DE60124131T2 (de) 2007-03-29
KR20080047628A (ko) 2008-05-29
SE0004124D0 (sv) 2000-11-10
ES2269480T3 (es) 2007-04-01
ATE343392T1 (de) 2006-11-15
NO20032056D0 (no) 2003-05-08
JP2004520276A (ja) 2004-07-08
KR100886728B1 (ko) 2009-03-04
EP1331938A1 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
DK1331938T3 (da) Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
NO20032674L (no) Isoindolin-1-on-glukokinase-aktivatorer
EP1500403A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
WO2004089416A3 (en) Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002083879A3 (en) Immunotherapy based on dendritic cells
WO2001096377A3 (en) Vaccine for congenital tremors in pigs
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20074062L (no) Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
EP1421945A4 (en) ABSORBENT / ADSORBENT OF BILARY ACID
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2006004696A3 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060135A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
Xiaoning et al. Optimization of ultrasonic assisted extraction of pleurotus eryngii polysaccharide by response surface methodology and its antifatigue activity.
WO2003032965A3 (en) Use of ace inhibitors for reducing type 2 diabetes in high risk patients
AR034374A1 (es) Combinacion de un inhibidor de ptpasa y un inhibidor de ace
Petersenn et al. The effects of pasireotide (SOM230) on glucose metabolism and growth hormone (GH) nadir during oral glucose tolerance test (OGTT) in 12 patients with acromegaly from a Phase II study